Genetics and epigenetics in major psychiatric disorders: dilemmas, achievements, applications, and future scope.
No specific gene has been identified for any major psychiatric disorder, including schizophrenia, in spite of strong evidence supporting a genetic basis for these complex and devastating disorders. There are several likely reasons for this failure, ranging from poor study design with low statistical power to genetic mechanisms such as polygenic inheritance, epigenetic interactions, and pleiotropy. Most study designs currently in use are inadequate to uncover these mechanisms. However, to date, genetic studies have provided some valuable insight into the causes and potential therapies for psychiatric disorders. There is a growing body of evidence suggesting that the understanding of the genetic etiology of psychiatric illnesses, including schizophrenia, will be more successful with integrative approaches considering both genetic and epigenetic factors. For example, several genes including those encoding dopamine receptors (DRD2, DRD3, and DRD4), serotonin receptor 2A (HTR2A) and catechol-O-methyltransferase (COMT) have been implicated in the etiology of schizophrenia and related disorders through meta-analyses and large, multicenter studies. There is also growing evidence for the role of DRD1, NMDA receptor genes (GRIN1, GRIN2A, GRIN2B), brain-derived neurotrophic factor (BDNF), and dopamine transporter (SLC6A3) in both schizophrenia and bipolar disorder. Recent studies have indicated that epigenetic modification of reelin (RELN), BDNF, and the DRD2 promoters confer susceptibility to clinical psychiatric conditions. Pharmacologic therapy of psychiatric disorders will likely be more effective once the molecular pathogenesis is known. For example, the hypoactive alleles of DRD2 and the hyperactive alleles of COMT, which degrade the dopamine in the synaptic cleft, are associated with schizophrenia. It is likely that insufficient dopaminergic transmission in the frontal lobe plays a role in the development of negative symptoms associated with this disorder. Antipsychotic therapies with a partial dopamine D2 receptor agonist effect may be a plausible alternative to current therapies, and would be effective in symptom reduction in psychotic individuals. It is also possible that therapies employing dopamine D1/D2 receptor agonists or COMT inhibitors will be beneficial for patients with negative symptoms in schizophrenia and bipolar disorder. The complex etiology of schizophrenia, and other psychiatric disorders, warrants the consideration of both genetic and epigenetic systems and the careful design of experiments to illumine the genetic mechanisms conferring liability for these disorders and the benefit of existing and new therapies.
Abdolmaleky
Hamid M
HM
Department of Psychiatry, Harvard Medical School at Massachusetts Mental Health Center, Boston, Massachusetts, USA. sayed_abdolmaleky@hms.harvard.edu
Thiagalingam
Sam
S
Wilcox
Marsha
M
D001921:Brain / Q000503:physiopathology; D015816:Cell Adhesion Molecules, Neuronal / Q000502:physiology; D004298:Dopamine / Q000502:physiology; D044127:Epigenesis, Genetic; D016326:Extracellular Matrix Proteins / Q000502:physiology; D005973:Glutamine / Q000502:physiology; D006801:Humans; D001523:Mental Disorders / Q000235:genetics* / Q000503:physiopathology; D008957:Models, Genetic; D009419:Nerve Tissue Proteins / Q000502:physiology; D010597:Pharmacogenetics; D017981:Receptors, Neurotransmitter / Q000235:genetics / Q000502:physiology; D000091042:Reelin Protein; D012697:Serine Endopeptidases / Q000502:physiology; D012701:Serotonin / Q000502:physiology
D015816:Cell Adhesion Molecules, Neuronal; D016326:Extracellular Matrix Proteins; D009419:Nerve Tissue Proteins; D017981:Receptors, Neurotransmitter; D000091042:Reelin Protein; D005973:Glutamine; D012701:Serotonin; C000717127:RELN protein, human; D012697:Serine Endopeptidases; D004298:Dopamine